Kadmon Holdings Priced, NYSE: KDMN

Developing kinase inhibitors for autoimmune disease, fibrosis and solid tumors.

Industry: Health Care

Latest Trade: $3.68 +0.13 (+3.7%)

First Day Return: -19.2%

Return from IPO: -70.4%

Industry: Health Care

We are a fully integrated biopharmaceutical company engaged in the discovery, development and commercialization of small molecules and biologics to address disease areas of significant unmet medical need. We are developing product candidates within autoimmune and fibrotic diseases, oncology and genetic diseases. We leverage our multi-disciplinary research and clinical development team members, who prior to joining Kadmon had brought more than 15 drugs to market, to identify and pursue a diverse portfolio of novel product candidates, through in-licensing products and employing our small molecule and biologics platforms. By retaining global commercial rights to our lead product candidates, we believe that we have the ability to progress these candidates ourselves while maintaining flexibility for commercial and licensing arrangements. We expect to continue to progress our clinical candidates and have further clinical trial events to report throughout 2016.
more less
IPO News for Kadmon Holdings
more
IPO Data
IPO File Date 06/10/2016
Offer Price $12.00
Price Range $12.00 - $12.00
Offer Shares (mm) 6.3
Deal Size ($mm) $75
IPO Data
IPO Date 07/26/2016
Offer Price $12.00
Price Range $12.00 - $12.00
Offer Shares (mm) 6.3
Deal Size ($mm) $75
Underwriters
more
Company Data
Headquarters New York, NY
Founded 2009
Employees 138
Website www.kadmon.com